Oncotarget

Research Papers:

The anti-apoptotic and prognostic value of fibroblast growth factor 9 in gastric cancer

Chuanli Ren _, Hui Chen, Chongxu Han, Deyuan Fu, Fuan Wang, Daxin Wang, Li Ma, Lin Zhou and Dongsheng Han

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:36655-36665. https://doi.org/10.18632/oncotarget.9131

Metrics: PDF 1789 views  |   HTML 2025 views  |   ?  


Abstract

Chuanli Ren1,6, Hui Chen2, Chongxu Han1, Deyuan Fu3, Fuan Wang4, Daxin Wang1, Li Ma5, Lin Zhou1, Dongsheng Han1

1Clinical Medical Testing Laboratory, Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University, Yangzhou, China

2Geriatric Medicine, Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University, Yangzhou, China

3Breast Oncology Surgery, Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University, Yangzhou, China

4Department of Interventional Radiography, Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University, Yangzhou, China

5Laboratory of Hematology, Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University, Yangzhou, China

6Department of Epidemiology and Biostatistics, Ministry of Education (MOE) Key Laboratory of Modern Toxicology, School of Public Health, Nanjing Medical University, Nanjing, China

Correspondence to:

Chuanli Ren, email: [email protected]

Keywords: gastric cancer, FGF9, apoptosis, prognosis

Received: October 10, 2015    Accepted: April 22, 2016    Published: May 2, 2016

ABSTRACT

Fibroblast growth factor (FGF) 9 is a member of the FGF family, which promotes carcinogenesis in some solid tumours. However, its biological and prognostic significance in gastric cancer (GC) is unclear. We examined FGF9 expression in 180 GC and corresponding non-tumorous gastric tissue samples by immunohistochemistry and evaluated its role in predicting tumour prognosis. Knockdown of FGF9 by siRNA inhibited cell growth and induced apoptosis in GC cell lines. Fifty of the 180 GC specimens (27.8%) had high FGF9 protein expression, whereas decreased or unchanged expression was observed in 130 cases (72.2%). High FGF9 expression was a significant predictor of poor survival (28.1 vs. 55.8 months, P < 0.001). After stratification according to AJCC stage, FGF9 remained a significant predictor of shorter survival in stage II (30.6 vs. 64.9 months, P < 0.001) and stage III GC (29.7 vs. 58.9 months, P < 0.001). Multivariate and univariate analysis showed that higher expression of FGF9 can be used as a predictor for poor prognosis (HR, 2.95; 95% CI, 1.97–4.41; P < 0.001; and HR, 2.94; 95% CI, 2.01–4.31; P < 0.001, respectively). FGF9 may provide the anti-apoptotic function and be useful as a novel independent marker for evaluating GC prognosis


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9131